Webinars

Dr Esther Nossent from Amsterdam UMC explains how PH-ILD develops, why it can be difficult to recognise when symptoms overlap with existing lung disease, and how it is investigated. She also discusses individualised treatment, supportive care and ongoing research.

Chaired by Louise Bouman, the panel discussion with Dr Nossent and Liam Galvin explores collaboration between ILD and pulmonary hypertension specialists, clear referral pathways and communication about tests and next steps. The discussion also covers reliable information, peer support, psychological support and the needs of families and carers.

For people living with PH-ILD, their families and carers, patient organisations and healthcare professionals.

This session brings together leading experts from the US, UK, and Netherlands to explore where the field is heading. All four talks point toward the same underlying shift in PAH care — from reactive, late-stage diagnosis and generalized treatment toward earlier detection, continuous monitoring, and individualized therapy, powered by AI and better data. For patients, that translates into the possibility of catching the disease sooner and getting treatment tailored to them specifically, rather than a standard protocol.

Programme

• Ioana R. Preston (USA)Integrating real-world and digital data for clinical decision-making
• Harm Jan Bogaard (Netherlands)Biomarkers for early detection and disease monitoring
• Martin Wilkins (UK)The path to personalised medicine
• Sudarshan Rajagopal (USA)New imaging approaches for screening and diagnosis of PH

The session opened with a welcome from Nils Fischer (USA) and closed with a live Q&A with the speakers.

The session brought together clinicians, researchers and patient advocates to discuss the future of PAH diagnosis and care.